arrow
R

Robert Wesolowski

the ohio state university comprehensive cancer center
H指数:34
被引数:4,811

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The gut microbiome in chemotherapy-induced fatigue: Exploring clinical associations and modulation via fecal microbiota transplantation in female mice

化疗诱导疲劳中的肠道微生物组:探讨临床相关性及通过粪菌移植在雌性小鼠中的调控

2026-08-230
OAAI
Primed to feel, not to flare: Early life adversity and psychological sensitivity to interleukin-6 in a randomized trial among middle-aged female breast cancer survivors

早期生活逆境与中老年女性乳腺癌幸存者对白细胞介素-6的心理敏感性:一项随机试验

2026-08-010
OAAI
Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer

Oncotype DX风险分层和化疗接受情况对微小淋巴结阴性HR+乳腺癌患者生存结局的影响

2026-07-150
OAAI
Gut microbiota and metabolite disruption during breast cancer chemotherapy is associated with peripheral neuropathy sensory symptoms and pain

肠道微生物组和代谢物紊乱与乳腺癌化疗期间的周围神经病变感觉症状和疼痛相关

2026-02-190
OAAI
BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy

Savardekar H, 等人. BRD4抑制可导致MDSC凋亡并增强检查点阻断疗法。临床研究杂志. (2025). doi: 10.1172/JCI181975

2025-10-012
OA
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

激素受体阳性、HER2阴性晚期乳腺癌患者在接受gedatolisib联合palbociclib和内分泌治疗(一项评估gedatolisib的1b期临床试验)治疗后的总生存期

2025-06-300
PRE
Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis

低激素受体表达对非转移性HER2阴性乳腺癌新辅助化疗反应及治疗模式的影响:一项美国国家癌症数据库分析

2025-06-090
OA
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

一项关于奈拉替尼联合或不联合氟维司群治疗HER2阳性、雌激素受体阳性转移性乳腺癌的随机II期研究

2025-05-160
PRE
Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors
2024-11-080
OA